A clinical trial attempts to standardize fetal cell transplantation and highlights challenges to be addressed in upcoming studies that use stem cell-derived neuron progenitors.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Barker, R. A. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02567-2 (2025).
Olanow, C. W. et al. Ann. Neurol. 54, 403–414 (2003).
Freed, C. R. et al. N. Engl. J. Med. 344, 710–719 (2001).
Dorsey, E. R. & Bloem, B. R. JAMA Neurol. 75, 9–10 (2018).
Armstrong, M. J. & Okun, M. S. JAMA 323, 548–560 (2020).
Li, W. et al. Proc. Natl Acad. Sci. USA 113, 6544–6549 (2016).
Politis, M. et al. Sci. Transl. Med. 2, 38ra46 (2010).
Nakamura, T. et al. Ann. Neurol. 50, 181–187 (2001).
Tabar, V. et al. Nature 641, 978–983 (2025).
Sawamoto, N. et al. Nature 641, 971–977 (2025).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V. Tabar is a scientific consultant for BlueRock Therapeutics.
Rights and permissions
About this article
Cite this article
Tabar, V. A trial of fetal cells for Parkinson’s disease brings lessons for the field. Nat Biotechnol 44, 40–41 (2026). https://doi.org/10.1038/s41587-025-02742-5
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02742-5
